Gary A Lewis

US Patent:

7973061, Jul 5, 2011

Filed:

Mar 31, 2005

Appl. No.:

10/598911

Inventors:

James William Leahy - San Leandro CA, US
Gary Lee Lewis - San Francisco CA, US
John M. Nuss - Danville CA, US
Brain Hugh Ridgway - Belmont CA, US
Joan C. Sangalang - Mountain View CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/41
A61K 31/415
C07D 249/00
C07D 257/04

US Classification:

514359, 514383, 514403, 548190, 548195, 548255, 5482622, 5483001, 549 79

Abstract:

The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R, R, Rand Rare defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions; (Formula I).

US Patent:

8222263, Jul 17, 2012

Filed:

Mar 14, 2008

Appl. No.:

12/049225

Inventors:

Suleyman Bahceci - San Mateo CA, US
William Bajjalieh - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Sergey Epshteyn - Fremont CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - New York NY, US
Byung Gyu Kim - San Mateo CA, US
James W. Leahy - San Leandro CA, US
Matthew Sangyup Lee - San Francisco CA, US
Gary L. Lewis - San Francisco CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - San Mateo CA, US
Charles K. Marlowe - Emerald Hills CA, US
Brian Hugh Ridgway - Belmont CA, US
Joan C. Sangalang - Mountain View CA, US
Xian Shi - San Bruno CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US

Assignee:

Exelixis Patent Company LLC - South San Francisco CA

International Classification:

A61K 31/517
A01N 43/54

US Classification:

51426621, 5142661, 5142641, 544276, 544283, 544286

Abstract:

The present invention is directed to a compound of Formula I.

US Patent:

8440663, May 14, 2013

Filed:

Jan 30, 2007

Appl. No.:

11/992224

Inventors:

Grace Mann - San Mateo CA, US
Naing Aay - San Mateo CA, US
Arlyn Arcalas - South San Francisco CA, US
S. David Brown - San Carlos CA, US
Wai Ki Vicky Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Hongwang Du - Millbrae CA, US
Sergey Epshteyn - Fremont CA, US
Timothy Patrick Forsyth - Hayward CA, US
Adam A. Galan - Alameda CA, US
Tai Phat Huynh - New York City NY, US
Mohamed Abdulkader Ibrahim - Mountain View CA, US
Henry William Beecroft Johnson - San Bruno CA, US
Brian Kane - Lynchburg VA, US
Patrick Kearney - San Francisco CA, US
Byung Gyu Kim - San Mateo CA, US
Elena S. Koltun - Foster City CA, US
James W. Leahy - San Leandro CA, US
Matthew Sangyup Lee - San Bruno CA, US
Gary L. Lewis - San Francisco CA, US
Lisa E. Meyr - Seattle WA, US
Robin Tammie Noguchi - San Bruno CA, US
Michael Pack - San Francisco CA, US
Brian Hugh Ridgway - Belmont CA, US
Xian Shi - San Bruno CA, US
John Woolfrey - Los Altos CA, US
Peiwen Zhou - Palo Alto CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/535
C07D 239/24
C07D 401/10
C07D 413/10

US Classification:

5142358, 544323, 544324, 544333

Abstract:

This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R, R, R, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

US Patent:

20110288076, Nov 24, 2011

Filed:

Oct 16, 2009

Appl. No.:

13/124604

Inventors:

Mohamed Abdulkader Ibrahim - Mountain View CA, US
Joon Won Jeong - Belmont CA, US
Henry William Beecroft Johnson - San Bruno CA, US
Patrick Kearney - San Francisco CA, US
James W. Leahy - San Leandro CA, US
Gary L. Lewis - San Francisco CA, US
Robin Tammie Noguchi - San Bruno CA, US
John M. Nuss - Danville CA, US

Assignee:

EXELIXIS, INC. - South San Francisco CA

International Classification:

A61K 31/4196
C07D 403/06
C07C 237/22
C07D 307/54
C07D 207/452
C07D 213/56
C07D 403/04
C07D 417/06
C07D 223/04
A61K 31/417
A61K 31/4192
A61K 31/167
A61K 31/341
A61K 31/4015
A61K 31/455
A61K 31/506
A61K 31/541
A61K 31/55
A61P 35/00
A61P 35/02
C07D 277/30

US Classification:

51421712, 548204, 548255, 5482676, 5482656, 564158, 549488, 548546, 546316, 546298, 544295, 544 585, 540610, 514400, 514422, 514383, 514616, 514471, 514425, 514355, 514350, 51425214, 5142278

Abstract:

This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particularly, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.

US Patent:

20120238570, Sep 20, 2012

Filed:

Jun 4, 2012

Appl. No.:

13/487559

Inventors:

Suleyman Bahceci - San Mateo CA, US
William Bajjalieh - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Sergey Epshteyn - Fremont CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - New York NY, US
Byung Gyu Kim - San Mateo CA, US
James W. Leahy - San Leandro CA, US
Matthew Sangyup Lee - San Francisco CA, US
Gary L. Lewis - San Francisco CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - San Mateo CA, US
Charles K. Marlowe - Emerald Hills CA, US
Brian Hugh Ridgway - Belmont CA, US
Joan C. Sangalang - Mountain View CA, US
Xian Shi - San Bruno CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US

Assignee:

EXELIXIS PATENT COMPANY LLC - San Francisco CA

International Classification:

A61K 31/517
A61K 31/519
C07D 413/04
A61P 35/00
C07D 239/84
C07D 471/04
C07D 403/12
A61K 31/5377
C07D 239/70

US Classification:

5142345, 5142581, 51426411, 5142662, 51426622, 51426623, 5142664, 544119, 544253, 544279, 544284

Abstract:

The present invention is directed to a compound of Formula Ior a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

US Patent:

20120245139, Sep 27, 2012

Filed:

Jun 4, 2012

Appl. No.:

13/487594

Inventors:

Suleyman Bahceci - San Mateo CA, US
William Bajjalieh - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Sergey Epshteyn - Fremont CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - New York NY, US
Byung Gyu Kim - San Mateo CA, US
James W. Leahy - San Leandro CA, US
Matthew Sangyup Lee - San Francisco CA, US
Gary L. Lewis - San Francisco CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - San Mateo CA, US
Charles K. Marlowe - Emerald Hills CA, US
Brian Hugh Ridgway - Belmont CA, US
Joan C. Sangalang - Mountain View CA, US
Xian Shi - San Bruno CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US

Assignee:

EXELIXIS PATENT COMPANY LLC - San Francisco CA

International Classification:

A61K 31/517
A61P 35/00
A61K 31/55
A61K 31/519
A61K 31/5377
A61K 31/553

US Classification:

51421018, 5142664, 5142662, 5142345, 51425217, 51426622, 51426621, 51426624, 51426623, 51421109, 51421706, 514249, 5142325, 51426411, 5142581

Abstract:

The present invention is directed to a compound of Formula Ior a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

US Patent:

20120278802, Nov 1, 2012

Filed:

Apr 28, 2011

Appl. No.:

13/096460

Inventors:

Chandrasekharan Nilakantan - Cupertino CA, US
Gary Lewis - San Jose CA, US
Lawrence Stein - San Carlos CA, US

Assignee:

DELL PRODUCTS L.P. - Round Rock TX

International Classification:

G06F 9/455

US Classification:

718 1

Abstract:

A method of automatically configuring a data network, the data network including a controller and a virtualization host with a hypervisor installed thereon, the method including creating a virtual switch in the hypervisor and communicatively coupling the virtual switch to a first physical network interface in the virtualization host. Further, the method includes receiving a request to boot an operating system image in a virtual machine in the hypervisor, the operating system image having network connectivity requirements. The method also includes creating a first virtual port in the virtual switch based upon the network connectivity requirements of the operating system image and creating a first virtual network adapter in the virtual machine in the hypervisor. Further, the method includes communicatively coupling the first virtual network adapter to the first virtual port in the virtual switch and configuring networking attributes of the first virtual network adapter in the virtual machine.

US Patent:

20150195129, Jul 9, 2015

Filed:

Mar 23, 2015

Appl. No.:

14/665025

Inventors:

- Round Rock TX, US
Gary Lewis - San Jose CA, US
Lawrence Stein - San Carlos CA, US

International Classification:

H04L 12/24

Abstract:

A method of automatically configuring a data network, the data network including a controller and a virtualization host with a hypervisor installed thereon, the method including creating a virtual switch in the hypervisor and communicatively coupling the virtual switch to a first physical network interface in the virtualization host. Further, the method includes receiving a request to boot an operating system image in a virtual machine in the hypervisor, the operating system image having network connectivity requirements. The method also includes creating a first virtual port in the virtual switch based upon the network connectivity requirements of the operating system image and creating a first virtual network adapter in the virtual machine in the hypervisor. Further, the method includes communicatively coupling the first virtual network adapter to the first virtual port in the virtual switch and configuring networking attributes of the first virtual network adapter in the virtual machine.